World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 3

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Methodol. Sep 26, 2014; 4(3): 163-188
Published online Sep 26, 2014. doi: 10.5662/wjm.v4.i3.163

Table 2 The largest health care companies in the world based on annual revenues

Rank	Company	Country	Total annual revenue(USD billions)
1	Johnson and Johnson	United States	61.90
2	Pfizer	United States	50.01
3	Roche	Switzerland	47.35
4	GlaxoSmithKline	United Kingdom	45.83
5	Novartis	Switzerland	44.27
6	Sanofi	France	41.99
7	Astra Zeneca	United Kingdom/Sweden	32.81
8	Abbott Laboratories	United States	30.76
9	Merck and Co.	United States	27.43
10	Bayer HealthCare	Germany	22.30
11	Eli Lilly	United States	21.84
12	Bristol-Myers Squibb	United States	18.81

The companies were ranked by revenue as of March 2010 according to their released 2009 annual reports.

Citation: Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol 2014; 4(3): 163-188
URL: https://www.wjgnet.com/2222-0682/full/v4/i3/163.htm
DOI: https://dx.doi.org/10.5662/wjm.v4.i3.163

Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol 2014; 4(3): 163-188 [PMID: 25332915 DOI: 10.5662/wjm.v4.i3.163]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.